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Abstract
Background: Inflammatory bowel disease (IBD) refers to a diverse group of chronic gastrointestinal diseases,
and gut microbial dysbiosis has been proposed as a modulating factor in its pathogenesis. Several studies have
investigated the gut microbial ecology of dogs with IBD but it is yet unclear if this microbial profile can alter the
nutrient metabolism of the host. The aim of the present study was to characterize the faecal bacterial profile and
functionality as well as to determine host metabolic changes in IBD dogs.
Twenty-three dogs diagnosed with IBD and ten healthy control dogs were included. Dogs with IBD were given a
clinical score using the canine chronic enteropathy clinical activity index (CCECAI). Faecal short-chain fatty acids
(SCFA) and ammonia concentrations were measured and quantitative PCR was performed. The concentration of
plasma amino acids, acylcarnitines, serum folate, cobalamin, and indoxyl sulfate was determined.
Results: No significant differences in the abundance of a selection of bacterial groups and fermentation metabolites
were observed between the IBD and control groups. However, significant negative correlations were found between
CCECAI and the faecal proportion of Lactobacillus as well as between CCECAI and total SCFA concentration. Serum
folate and plasma citrulline were decreased and plasma valine was increased in IBD compared to control dogs.
Increased plasma free carnitine and total acylcarnitines were observed in IBD compared with control dogs, whereas
short-chain acylcarnitines (butyrylcarnitine + isobutyrylcarnitine and, methylmalonylcarnitine) to free carnitine ratios
decreased. Dogs with IBD had a higher 3-hydroxyisovalerylcarnitine + isovalerylcarnitine to leucine ratio compared to
control dogs.
Conclusions: Canine IBD induced a wide range of changes in metabolic profile, especially for the plasma concentrations
of short-chain acylcarnitines and amino acids, which could have evolved from tissue damage and alteration in
host metabolism. In addition, dogs with more severe IBD were characterised by a decrease in faecal proportion of
Lactobacillus.
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Background
Canine idiopathic inflammatory bowel disease (IBD) is a
group of disorders characterized by persistent or recur-
rent clinical signs of gastro-intestinal disease of undeter-
mined cause associated with histological evidence of
inflammation in the small or large intestinal mucosa [1].
It has been considered to be the most common cause of
chronic diarrhoea and vomiting in dogs [2]. Gut micro-
biota play a critical role in host-microbial interactions
and gut health. Gut dysbiosis, an unbalanced microbiota
composition, is often seen in dogs with IBD and may
contribute to the pathogenesis of this disease [3–7]. In
humans, IBD has been associated with a decrease in
butyrate-producing bacteria including the major butyrate
producing bacteria, clostridial cluster IV and XIVa,
Faecalibacterium prausnitzii, and the terminal gene to
produce butyrate, butyryl-CoA acetate-CoA transferase
(BCoAT) gene [8–10]. Similarly, a lower abundance of
Faecalibacterium spp. has been reported in dogs with
IBD [4, 7]. However, the relative proportion of Faecali-
bacterium is much lower in healthy dogs compared to
humans [7, 11, 12]. Therefore, assessing the major butyr-
ate producing clusters and the functional gene that
expresses BCoAT gene could be important in exploring
the role of butyrate producing bacteria in canine IBD.
The changes in the gut microbial populations in IBD
are becoming clearer [3–7], however, the functional rela-
tionship between microbes and the host is less well
understood in both humans and dogs. A major function
of gut microbiota is degradation of non-digestible dietary
residues, yielding fermentation end-products which can
be beneficial or harmful to the host, such as short-chain
fatty acids (SCFA) and putrefactive substances. Several
studies have shown changes in fermentation metabolites
in humans IBD patients [13–15]. However, no study has
investigated the fermentation end products in dogs with
IBD yet. Further, gut-derived SCFA are rapidly absorbed
from the gut lumen and enter into systemic circulation
at different concentration. Based on the concentrations
in peripheral and portal blood, about 75 % of acetate,
90 % of propionate and 95 % of butyrate are taken up
during a single pass of blood through the human liver
[16]. The metabolism of SCFA requires activation of co-
enzyme (Co) A and intracellular CoA bound acylgroups
are then transported from the cytoplasm to the mito-
chondria by carnitine groups [17]. Hence, short-chain
acylcarnitines (i.e. acetylcarnitine, propionylcarnitine,
butyrylcarnitine) are measures of respective SCFA-CoA
and reflect the major pathways by which SCFA influence
cellular metabolism [18].
Host metabolic differences have been reported in both
animals and humans. Canine IBD was associated with
increased serum abundance of 3-hydroxybutyrate, hex-
uronic acid, and gluconic acid lactone [3]. Similarly, an
ulcerative colitis (UC) mice model showed an increase
in serum ketone bodies, a drop in serum glucose as well
as decreases in several amino acids (e.g. tyrosine, glu-
tamine, and alanine) [19]. An altered amino acid profile
was also observed in both UC and Crohn’s disease (CD)
patients, with for instance, increased levels of isoleucine
and decreased valine in serum [20]. Thus, IBD is charac-
terised by significant changes in host metabolites in
humans but data are still lacking for canine IBD.
Although several studies investigated the microbial
ecology of IBD patients [3–7], it is yet unclear if the al-
tered microbial profile also results in an altered nutrient
metabolism of the host. The aim of the study was to
evaluate faecal microbial profile and functionality espe-
cially focussing on butyrate-producing microbiota and
the concomitant fermentation and host metabolic profile
in dogs with IBD. We hypothesized that canine IBD is
associated with changes in faecal microbial and meta-
bolic profile. The findings of this study might provide
potential interesting candidates for diagnosing IBD in
both humans and dogs.
Methods
Animals
The European Directive 2010/63/EU and institutional
guidelines of Belgian Council for Laboratory Animal
Science for the care and use of animals were followed.
The present study used opportunistic sampling in the
IBD dogs that were presented in the clinic as no add-
itional manipulations were needed besides the necessary
procedure for normal diagnosis and treatment. For the
control dogs, samples were collected after euthanasia for
reasons not related to the study, thus, an approval from
the Ethical Committee (of the Faculty of Veterinary
Medicine, Ghent University, Belgium) was not required.
Informed written consent was obtained from the owners
of all IBD dogs participating in the study and all dogs re-
ceived a high standard of veterinary care.
Twenty-three dogs, 15 admitted at the Small Animal
Clinic of Ghent University (Belgium) and eight at a local
private small animal clinic ‘Dierenartsencentrum Hond
en Kat’, Astene (Belgium), diagnosed with IBD were in-
cluded in the IBD group. The minimum diagnostic
evaluation performed in all IBD dogs included complete
blood counts, serum biochemistry, urinalysis, faecal
parasitology, abdominal ultrasound, and histopathologic
review of mucosal biopsy specimens. The inclusion cri-
teria for the IBD group were adapted from World Small
Animal Veterinary Association [2]: (1) chronic (> three
weeks) persistent or recurrent gastrointestinal signs such
as but not limited to vomiting and diarrhoea; (2)
histopathologic evidence of mucosal inflammation; (3) in-
ability to document other causes of gastrointestinal in-
flammation; (4) inadequate response to dietary, antibiotic
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and anthelmintic therapies alone. The requirement of the
clinical response to anti-inflammatory or immunosuppres-
sive agents was not included because anti-inflammatory
drugs may influence gut microbiota [21]. Additionally, no
dogs received antibiotics for at least three weeks before
sampling.
Dogs with IBD were allocated a clinical score using
the canine chronic enteropathy clinical activity index
(CCECAI) [22]. Briefly, the CCECAI score is based on
nine criteria, each scored on a scale from 0–3: attitude/
activity, appetite, vomiting, stool consistency, stool fre-
quency, weight loss, albumin levels, ascites and peripheral
edema, pruritus. After summation, the total score is deter-
mined to be clinically insignificant (0–3), mild (4–5),
moderate (6–8), severe (9–11), or very severe (≥12) IBD.
Ten healthy dogs, four from the Department of Med-
ical Physiology, University Medical Centre Utrecht (The
Netherlands) and six from an animal shelter (Wase Dier-
enbescherming, Sint-Niklaas, Belgium) were included in
the control group. The control dogs were euthanized for
research purposes unrelated to the present study or for
behavioural problems. All dogs were deemed healthy
based on physical exams, complete blood counts, and
serum biochemistry and none of the dogs received anti-
biotic treatment for at least three weeks before sampling.
Sample collection
At presentation in the clinic for IBD dogs, and immedi-
ately after euthanasia for control dogs, blood samples
(5 mL, normally taken for general health check-up) were
drawn from the jugular vein. Plasma and serum were
obtained from all dogs, except for one IBD dog (due to
improper sample storage) by centrifugation at 1620 g for
15 min at 4 °C and stored at – 20 °C until analysis. Upon
diagnosis, faecal samples were collected from 15 dogs in
the IBD group by natural voiding of faeces or by use of
rectal swabs. For all dogs in the control group, faecal
samples were obtained from the rectum immediately
after euthanasia. All faecal samples were frozen in dry
ice and stored at – 80 °C until analysis.
Analytical methods
Serum cobalamin and folate concentrations were ana-
lyzed by a commercial laboratory (Algemeen Medisch
Laboratorium, Antwerp, Belgium) using commercially
available ARCHITECT B12 and ARCHITECT Folate as-
says on ARCHITECT i System (Abbott Diagnostics).
Plasma amino acids and acylcarnitine profile was deter-
mined according to Zytkovicz et al. [23]. Faecal SCFA
concentrations were determined via gas chromatography
after extraction with diethyl ether [24]. Ammonia was
analyzed by steam distillation and titration according to
Bremner and Keeney [25].
Bacterial DNA extraction
Bacterial DNA extraction of the faecal samples was per-
formed according to Vanhoutte et al. [26]. DNA concen-
tration was measured in triplicate using the Nanodrop
ND 1000 spectrophotometer (NanoDrop Technologies).
Quantitative PCR
DNA quantification by qPCR was performed using the
C1000 Thermal Cycler (Bio-Rad, Hercules CA, USA).
The amplification and detection were carried out in 96-
well plates using SensiMixTM SYBR No-ROX Kit (Bio-
line Reagents Ltd, UK). Each reaction was done in tripli-
cate in 12 μL total reaction mixture using 2 μL of 50 ng
of the DNA sample. The primer sets used in this study
are listed in Table 1. A melting curve analysis was done
after amplification to confirm specificity of the reaction.
The quantification was done using standard curves made
from known concentrations of plasmid DNA containing
the respective amplicon for each set of primers.
Calculations
Total acylcarnitines were calculated as the sum of
plasma concentration of acetylcarnitine (C2), propionyl-
carnitine (C3), butyrylcarnitine and isobutyrylcarnitine
(C4), tiglylcarnitine, isovalerylcarnitine and methylbutyryl-
carnitine (C5), 3-hydroxybutyrylcarnitine (3OH-C4), 3-
hydroxyisovalerylcarnitine and 2-methyl-3-hydroxybutyr-
ylcarnitine (3OH-C5), methylmalonylcarnitine (C4DC),
hexanoylcarnitine, octanoylcarnitine, malonylcarnitine,
decenoylcarnitine, decanoylcarnitine, glutaryl- and 3OH-
decanoylcarnitine, dodecanoylcarnitine, methylglutarylcar-
nitine, 3OH-dodecanoylcarnitine, tetradecadienoylcarnitine,
tetradecenoylcarnitine, tetradecanoylcarnitine, suberyl-
carnitine, 3OH-tetradecenoylcarnitine, 3OH-tetradecanoyl
carnitine, hexadecenoylcarnitine, palmitoylcarnitine, seba-
cylcarnitine, 3OH-hexadecenoylcarnitine, 3OH-palmitoy
lcarnitine, octadienoylcarnitine, octadecenoylcarnitine, octa
decanoylcarnitine, 3OH-octadecenoylcarnitine and 3OH-
octadecanoylcarnitine.
The ratios of individual acylcarnitines to C0 were used
to determine the host metabolic changes. Two specific
ratios representing amino acid metabolism were also cal-
culated: (C5 + 3OHC5)/leucine and citrulline/ornithine.
Faecal total SCFA concentration was calculated as the
sum of acetate, propionate, butyrate, valerate, isobutyrate
and isovalerate. The proportions of individual SCFA
were expressed relative to total SCFA.
Normalization of qPCR data was expressed by all
qPCR data relative to the amount of total bacterial
measured.
Statistical analyses
Data were analysed using the Wilcoxon-Mann–Whitney
test to compare difference between two groups. For this,
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four data sets were built: one with all parameters
measured in faeces, one with all the ratios calculated
from the faecal parameters, one with all metabolites
assessed in the blood, and one with all the ratios cal-
culated from the blood. For each data set, the
Wilcoxon-Mann–Whitney test was run separately. To
correct for false discovery rates, P values were ad-
justed (q value) using the Benjamini-Hochberg test.
Valerate was only detected in two faecal samples in
IBD dogs hence this parameter was not taken into
consideration in the statistical analysis. These analyses
were done in R (The R Foundation for Statistical
Computing, version 3.1.0) using the Coin package
(version1.0–23).
Spearman correlations coefficients were calculated be-
tween CCECAI and the abundance of different bacterial
groups, faecal fermentation end products, plasma amino
acids and acylcarnitine profile. The CCECAI score
assigned to control dogs was zero (0). Spearman correl-
ation analysis was performed using SPSS version 20
(SPSS Inc., Chicago, Illinois, USA).
For all parameters, statistical significance was accepted
at P < 0.05 and q < 0.05.
Results
Study population and CCECAI scores
The IBD group consisted of seven intact females,
four spayed females, nine intact males and three
neutered males (0.8-12.3 years, median age: 3.8 years).
Breeds included Dogue de Bordeaux, Spanish Water
Dog, Galgo Español, Golden Retriever, Sheltie, Jack
Russell Terrier, Miniature Pinscher, Foxhound,
Eurasier, Alaskan Malamute, Bouvier des Flandres,
Husky, Great Swiss Mountain Dog, Whippet, Stand-
ard Poodle, Lapphund, German Shepherd, Rottweiler,
Bichon Frise, Beagle, French Bulldog and Mongrel
dogs (×2). Five dogs had insignificant IBD (median
CCECAI = 2.0), five dogs had mild IBD (median
CCECAI = 5.0), six dogs had moderate IBD (CCE-
CAI = 8.0) and seven dogs had severe IBD (median
CCECAI =10).
The control group consisted of five intact females and
five intact males (0.5–8.0 years, median age: 2.3 years).
Breeds included American Staffordshire Terrier, Staf-
fordshire Bull Terrier, German Shepherd, Scottish Collie,
Labrador Retriever, Jack Russell Terrier, Beagle, and
Mongrel dogs (×3).
Table 1 Primer set used in the present study
Target Primers (5’→ 3’) References
Bacteria V3 region PRBA338f ACTCCTACGGGAGGCAGCAG [49]
PRUN518r ATTACCGCGGCTGCTGG
Total Bacteria fwd CGGYCCAGACTCCTACGGG [50]
rev TTACCGCGGCTGCTGGCA
Firmicutes fwd GGAGYATGTGGTTTAATTCGAAGCA [51]
rev AGCTGACGACAACCATGCAC
Enterobacteriaceae fwd CATTGACGTTACCCGCAGAAGAAGC [52]
rev CTCTACGAGACTCAAGCTTGC
Bacteriodetes fwd GGARCATGTGGTTTAATTCGATGAT [51]
rev AGCTGACGACAACCATGCAG
Lactobacillus fwd GGAATCTTCCACAATGGACG [53]
rev CGCTTTACGCCCAATAAATCCGG
Clostridial cluster I fwd TACCHRAGGAGGAAGCCAC [54]
rev GTTCTTCCTAATCTCTACGCAT
Clostridial cluster IV fwd ATGCAAGTCGAGCGA(G/T)G [55]
rev TATGCGGTATTAATCT(C/T)CCTTT
Clostridial cluster XIVa fwd CGGTACCTGACTAAGAAG [56]
rev AGTTT(C/T)ATTCTTGCGAAC
Butyryl-CoA acetate-CoA transferase fwd AAGGATCTCGGIRTICAYWSIGARATG) [57]
rev GAGGTCGTCICKRAAITYIGGRTGNGC
Dissimilative sulphate-reducing bacteria gene fwd AACAACATHGARTTYATG [58]
rev TAGCAGTTACCRCARTACAT
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Faecal microbiota
No differences were found between IBD and control
dogs for the relative abundance of Firmicutes, Bacteroi-
detes, Enterobacteriaceae, Lactobacillus, clostridial clus-
ter I, IV and XIVa in faecal samples, nor for the number
of gene copies of butyryl-CoA acetate-CoA transferase
(BCoAT) and dissimilative sulphate-reducing bacteria
gene (dSRB) (q > 0.05) (Table 2).
Correlations between CCECAI scores and bacterial
groups revealed a negative correlation with relative fae-
cal abundance of Lactobacillus (r = −0.504, P = 0.010)
(Fig. 1a).
Faecal fermentation metabolites
No differences were observed between IBD and control
dogs for faecal ammonia and SCFA concentrations
(q > 0.05; Table 3). Spearman’s correlation showed
only a negative correlation between faecal total SCFA
concentrations and CCECAI scores (r = −0.489, P = 0.013)
(Fig. 1b).
Blood parameters
Serum cobalamin concentrations did not differ between
the IBD and control group, while serum folate concen-
trations were lower in the IBD compared to the control
group (q = 0.023) (Table 4). The IBD group also showed
increased plasma valine concentrations (q = 0.003),
whereas plasma citrulline concentrations (q = 0.016) and
citrulline/ornithine ratios (q = 0.014) were decreased in
IBD compared to control dogs (Table 4). Also plasma
C0 (q = 0.003) and total acylcarnitine (q = 0.003) concen-
trations were increased in IBD compared to control dogs
(Table 4). As for the ratios of individual plasma acylcarni-
tines to C0, C4/C0 (q = 0.008) and C4DC/C0 (q = 0.006)
were decreased, while (C5 + 3OHC5)/leucine (q = 0.006)
were increased in IBD compared to control group
(Table 4). For C3/C0 and 3OHC4/C0 no significant differ-
ence was observed between groups (Table 4).
Negative correlations between CCECAI scores and
C4/C0 (r = −0.496, P = 0.004), and between CCECAI
scores and plasma citrulline concentrations (r = −0.578,
P = 0.001) were observed (Fig. 1c and d). In addition,
positive correlations were noted between CCECAI
scores and plasma valine (r = 0.613, P < 0.001), and be-
tween CCECAI scores and plasma alanine (r = 0.374,
P = 0.035) concentrations (Fig. 1e and f ).
Discussion
This study aimed to provide new insights into the rela-
tionship between faecal microbiota profile and their
functionality, and host metabolic changes in canine IBD.
Although changes in gut microbiota, and in particular
the numbers of Faecalibacterium spp. have been repeat-
edly reported to be decreased in IBD dogs [4, 7], no
major changes in faecal microbiota have been observed
in this study. In addition, butyrate producing bacteria
were also not affected by the disease status in the
present study. The fact that no significant differences
were observed in faecal microbiota between IBD and
control dogs could be due to three main reasons: (1) A
large inter-individual variability among dogs may exist
and has been observed in other canine studies [27, 28].
The sources of the variation may include gender, age,
breed, living conditions (e.g. exposure to pathogens,
people, or other animals), diet (e.g. macronutrients com-
position or form) and disease activity. To search for
breed and age matched IBD and healthy dogs was the
initial goal of the study but was impossible to put into
practice. More standardized requirements (e.g. diet and
living condition) might reduce the large inter-individual
variability among dogs. (2) The methodology that was
used (i.e. DNA extraction and qPCR). Although qPCR is
the most accurate culture-independent measure of the
microbial abundance [29], 16S rRNA sequencing and
metagenomic sequencing could provide a more in-depth
characterisation of overall faecal microbiota shifts,
whereas the latter can determine the microbiome in
terms of potential functions.(3) Sample types. Most
studies using duodenal biopsies have detected distinct
differences in gut microbial community between IBD
and healthy dogs [5, 6]. Although faecal samples are
non-invasive to obtain, it remains a debate if faecal
microbiota data appropriate to study gut microbiota ac-
curately [30, 31].
Table 2 The faecal abundance of bacterial groups and functional
gene in IBD and control dogs. (IBD: n = 15, Control: n = 10)a
Control IBD q
valueMean SD Mean SD
Absolute valuea
Total bacteria 10.49 0.74 10.48 0.59 0.860
Relative value (%)b
Firmicutes 110.6 30.8 127.2 42.1 0.790
Bacteroidetes 35.5 44.6 52.2 51.9 0.823
Enterobacteriaceae 0.6 1.0 3.1 5.5 0.937
Lactobacillus 8.7 10.4 1.1 3.5 0.145
Clostridial cluster I 13.1 23.9 13.0 16.3 0.790
Clostridial cluster IV 9.4 9.7 8.5 12.5 0.937
Clostridial cluster XIVa 6.1 5.3 8.4 8.6 0.790
BCoAT 0.090 0.083 0.061 0.071 0.823
dSRB 0.002 0.001 0.001 0.002 0.608
IBD: inflammatory bowel disease; BCoAT: butyryl-CoA acetate-CoA transferase
gene; dSRB: dissimilative sulphate-reducing bacteria gene
aResults of bacterial groups are expressed as log1016S rRNA gene copies/g
fresh weight
bThe relative values are expressed as the ratio of the abundance of bacteria to
the abundance of total bacteria
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Nevertheless, the relative abundance of Lactobacillus
gradually decreased with increased severity of IBD in
dogs (Fig. 1). A reduction in faecal Lactobacillus has
been previously reported in human IBD patients [32].
Several Lactobacillus strains have been proven to effect-
ively protect against IBD in murine models through
down-regulation of pro-inflammatory cytokines [33, 34].
Although no difference in abundance of Lactobacillus
has been observed previously [3], the probiotic VSL#3
containing several strains of Lactobacillus and other bac-
terial strains showed a potential protective effect in IBD
dogs [4]. Therefore, more in-depth studies are needed to
identify the Lactobacillus strains that are altered in ca-
nine IBD.
Folate absorption occurs in the jejunum and abnor-
malities of the proximal small intestinal mucosa may
lead to reduced serum folate concentrations [35], as seen
in IBD dogs included in the present study. In addition,
gut commensals including Bifidobacteria and Lactobacil-
lus can produce folate [36]. Therefore, decreased serum
folate concentrations may be a consequence of impaired
intestinal function and/or altered gut microbial
community (e.g. the observed decrease in the abundance
of Lactobacillus). Whether alteration in Lactobacillus
Fig. 1 Correlations between canine chronic enteropathy clinical activity index (CCECAI) and several parameters. a The relative faecal abundance
of Lactobacillus (n = 25); b total faecal SCFA concentrations (n = 25); c the ratio of plasma C4 (butyrylcarnitine + isobutyrylcarnitine) to C0 (free
carnitine) (n = 32); d plasma valine (n = 32); e plasma citrulline (n = 32); and f plasma alanine concentrations (n = 32). Figure illustration: The faecal
proportions of Lactobacillus are negatively correlated with CCECAI scores a; the total SCFA concentrations are negatively correlated with CCECAI
scores b; the C4/C0 ratios are negatively correlated with CCECAI scores c; the plasma citrilline concentrations are negatively correlated with
CCECAI scores d; the plasma valine concentrations are positively correlated with CCECAI scores e; the plasma alanine concentrations are negatively
correlated with CCECAI scores f
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contributes to a decrease in serum folate needs further
investigation.
In this study, IBD dogs were characterized by distinct-
ive metabolic profile with changes in plasma free amino
acids and acylcarnitines. This could be due to two
possible reasons: (1) tissue damage, and (2) host meta-
bolic changes. Eighteen out of 23 IBD dogs experienced
different magnitude of weight loss (see Additional file 1),
which suggested the occurrence of tissue loss, e.g. the
adipose tissue and lean mass. Extreme weight loss with
muscle wasting (known as “cachexia”) may occur in dogs
with severe IBD [37]. In addition, intestinal mass might
be reduced as citrulline mainly originates from duode-
num and jejunum, and its blood level is highly
dependent on small bowel enterocytes mass in humans
[38]. However, inter-species difference on citrulline con-
version may exist [39]. Free carnitine and acylcarnitine
concentrations in tissues (muscle, intestine, etc.) are
higher than in the blood [40–42]. Thus, tissue loss might
lead to an increase in plasma C0 and total acylcarnitine
concentrations in IBD dogs. On the other hand, these
results might suggest an alteration on host metabolism.
Use of fat stores for ketone production and direct oxida-
tion of fat as a primary fuel are characteristic of starva-
tion. Previous study reported increased ketone body in
dogs with IBD, which suggested an energy insufficiency
[3]. Additionally, prolonged fasting was associated with
increased plasma and muscle free carnitine and total
carnitine in dogs [43]. Thus, the use of amino acids and
fatty acids as energy source might be expected in dogs
with IBD.
Moreover, IBD dogs showed reduced plasma C4/C0 and
this decrease was associated with the severity of IBD. This
could indicate a drop in butyrate and/or isobutyrate me-
tabolism in liver [18, 44]. Additionally, the ratio of C4DC,
which originates from valine and propionate [44], to C0
was also declined in IBD dogs. The drop of C4DC was
more likely due to a lack of propionate because plasma
valine was significantly increased. These results are in ac-
cordance with previous studies in humans that demon-
strated short-chain acylcarnitines, including C3, C4 and
C5, to be significantly lower in CD and UC patients com-
pared to healthy controls [45, 46]. The decreases of these
short-chain acylcarnitines are supported by decreased
SCFA in more severe IBD dogs. Although faecal SCFA did
not differ between IBD and control dogs, this could be
due to rapid absorption of SCFA leaving only a small de-
tectable amount in faeces. It is not known if the SCFA de-
rived from intestinal fermentation are a substantial source
of energy in dogs, but the shifts at least point to a change
in nutrient metabolism that is associated with the events
in the intestinal lumen.
Inflammatory conditions are known to stimulate pro-
tein catabolism and release amino acids from muscle tis-
sue to provide substrate for proteins of the immune
system [19]. Alanine is an important transport metabol-
ite for amino groups in animals, therefore, increased
concentrations of alanine might indicate a higher amino
acid turnover [44, 47]. In addition, increased plasma
Table 3 Faecal concentrations of fermentation end-products in
IBD and control dogs. (IBD: n = 15, Control: n = 10)a
Control IBD q
valueMean SD Mean SD
Acetate (%) 63.0 11.6 61.9 11.8 0.937
Propionate (%) 26.6 10.5 24.8 12.0 0.937
Butyrate (%) 7.0 3.7 10.1 4.4 0.726
Isobutyrate (%) 1.5 1.4 0.8 1.0 0.608
Isovalerate (%) 1.8 2.4 1.5 1.7 0.937
Ammonia (μmol/g) 324 195 238 86 0.843
Total SCFA (μmol/g) 123.9 36.9 80.1 39.7 0.145
IBD: inflammatory bowel disease; SCFA: short-chain fatty acids
aThe relative values are expressed as the ratio of individual SCFA to total SCFA
Table 4 Blood parameters of IBD and control dogs. (IBD: n = 15,
Control: n = 10)
Control IBD q
valueMean SD Mean SD
Cobalamin (pmol/L)a 285 68.1 301 213 0.651
Folate (pmol/L)b 34.5 6.75 24.0 11.5 0.023
Indoxyl sulfate (mg/dL) 1.56 1.05 1.57 1.65 0.681
Plasma amino acids
Valine (μmol/L) 213 43.1 287 53.8 0.003
Leucine (μmol/L) 257 58.3 274 61.0 0.536
Ornithine (μmol/L) 32.6 7.42 37.7 8.41 0.187
Citrulline (μmol/L) 112 48.1 71.3 39.0 0.016
Citrulline/Ornithine 3.53 1.77 2.00 1.07 0.014
Plasma acylcarnitine profile
C0 (μmol/l) 16.2 13.7 36.1 21.9 0.003
Total acylcarnitines (μmol/L) 2.16 1.03 4.00 1.84 0.003
Total acylcarnitines/C0 (%) 16.4 6.9 12.4 4.7 0.113
C2/C0 (%) 11.0 4.8 7.6 3.6 0.096
C3/C0 (%) 0.587 0.483 0.749 0.796 0.643
C4/C0 (%) 0.606 0.248 0.316 0.149 0.008
C4DC/C0 (%) 0.374 0.172 0.179 0.103 0.006
3OHC4/C0 (%) 0.111 0.083 0.119 0.078 0.874
(C5 + 3OHC5)/Leucine (%) 0.034 0.028 0.060 0.024 0.006
IBD: inflammatory bowel disease; C0: free carnitine, C2: acetylcarnitine, C3:
propionylcarnitine, C4: butyrylcarnitine + isobutyrylcarnitine, C4DC:
methylmalonylcarnitine, 3OHC4: 3-hydroxybutyrylcarnitine, C5: isovalerylcarni-
tine +methylbutyrylcarnitine,
3OHC5: 3-hydroxyisovalerylcarnitine + 2-methyl-3-hydroxybutyrylcarnitine
aReference range of cobalamin: 73–485 pmol/L. One dog in IBD group is out
of reference range
bReference range of folate: 9.0–36.0 nmol/L. Five dogs in IBD group and four
dogs in control group are out of reference range
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valine concentrations and (C5 + 3OHC5)/leucine ratios
might be associated with the increase in branched-chain
amino acids catabolism in the host [43]. However, a de-
crease in serum alanine has been observed in dextran
sulfate sodium induced UC mice [19] and decreases in
serum valine have been reported in both UC and CD
human patients [20]. The reason for the different obser-
vations between dogs and other species is not known.
However, alteration in plasma amino acids concentration
could also be involved with increased mobilisation from
lean tissues. In contrast, a decrease in plasma citrulline/
ornitine ratio suggested decreased protein catabolism.
This contradicted with the previous suggestion of in-
creased degradation. As mentioned previously, citrulline
is an amino acid released exclusively from small bowel
enterocytes, a disease condition involving the upper
intestine could reduce its production in humans [48].
Notably, an increased citrulline level was observed in
dogs with IBD that received probiotic treatment com-
pared to untreated dogs [4]. Therefore, future studies
are warranted to evaluate if plasma citrulline could be a
putative marker of intestinal function in canine IBD.
Conclusions
Canine IBD is characterised by significant changes in the
nutritional metabolic profile especially in the SCFA and
amino acids metabolism. A decrease in citrulline is
highlighted in this study and warrants for future studies
to test if it could be a putative marker of intestinal
function in canine IBD. However, in contrast to previ-
ous studies, no major changes in the bacterial groups
were observed in the present study. This could be
mainly due to the large inter-individual variability and
the technique used. Nevertheless, dogs with more se-
vere of IBD were associated with decreased faecal
proportion of Lactobacillus.
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Additional file 1: Canine chronic entreropathy clinical activity index in
IBD dogs. Description of data: the total CCECAI score and the individual
score of each criterion. (XLSX 9 kb)
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